Application of abnormal sweating stopping granules in preparation of medicine for adjuvant treatment of iron-deficiency anemia

A traditional Chinese medicine composition, combining astragalus, floating wheat, jujube, and calcined oyster, addresses the limitations of iron supplements by enhancing efficacy and safety in treating iron deficiency anemia in children.

CN119055731APending Publication Date: 2024-12-03GUANGZHOU BAIYUNSHAN QIXING PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411520765.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-29
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current treatments for iron deficiency anemia, particularly in children, suffer from low bioavailability, significant gastrointestinal side effects, and adverse reactions, limiting their clinical application.

Method used

A traditional Chinese medicine composition comprising astragalus, floating wheat, jujube, glutinous rice root, and calcined oyster, combined with oral iron supplements, to enhance iron absorption and reduce adverse reactions.

Benefits of technology

The Chinese medicine composition effectively improves blood routine indicators and serum iron metabolism, reduces adverse reactions, and enhances treatment efficacy in children with iron deficiency anemia, outperforming iron supplements alone.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention relates to an application of granules for treating abnormal sweating in preparation of a medicine for adjuvant treatment of iron-deficiency anemia, and the granules for treating abnormal sweating in abnormal sweating comprise the following raw materials: astragalus membranaceus, light wheat, Chinese dates, glutinous rice roots and calcined oyster shells. The traditional Chinese medicine composition has the advantages of obvious effect, low adverse reaction occurrence rate and good safety when being used for adjuvant treatment of iron-deficiency anemia, especially children iron-deficiency anemia, and the curative effect is superior to that of a single iron agent after being combined with the oral iron agent for treatment of children iron-deficiency anemia, which is specifically reflected in that the traditional Chinese medicine composition can effectively improve blood routine indexes and serum iron metabolism indexes of sick children, and can be used for treating children iron-deficiency anemia, especially children iron-deficiency anemia. The traditional Chinese medicine symptom score and the adverse reaction incidence rate are improved, the total effective rate of treatment is improved, and the safety is good.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of traditional Chinese medicine, and in particular to the use of a traditional Chinese medicine composition in the preparation of a medicine for the auxiliary treatment of iron deficiency anemia. Background Art

[0002] Iron deficiency anemia (IDA) is the most common type of anemia, which is caused by the body's lack of iron and reduced hemoglobin synthesis. Iron deficiency anemia usually presents with non-specific symptoms such as weakness, fatigue, inattention and low work efficiency, so it is often missed in clinical practice. The causes of iron deficiency anemia mainly include insufficient iron intake, malabsorption, iron utilization disorders and increased loss. Perinatal risk factors, dietary factors, and gastrointestinal diseases may aggravate iron deficiency. Iron deficiency anemia can cause neurodevelopmental abnormalities and cognitive impairment, so timely diagnosis and treatment are extremely important. Oral iron is a convenient, economical and effective method for the treatment of iron deficiency anemia, but common adverse reactions include nausea, vomiting, constipation, black stools, and black teeth. In addition, iron treatment has low bioavailability and obvious gastrointestinal reactions, which limits its clinical application. Summary of the invention

[0003] Based on this, it is necessary to provide a Chinese medicine composition for use in the preparation of a drug for the auxiliary treatment of iron deficiency anemia, wherein the Chinese medicine composition has the advantages of obvious effect, low incidence of adverse reactions and good safety in the auxiliary treatment of iron deficiency anemia.

[0004] The technical solution of this application is as follows:

[0005] The invention provides an application of a traditional Chinese medicine composition in preparing a medicine for auxiliary treatment of iron deficiency anemia. The traditional Chinese medicine composition comprises the following raw materials: astragalus, floating wheat, jujube, glutinous rice root and calcined oyster.

[0006] In one embodiment, the Chinese medicine composition includes the following raw materials, measured by mass: 18-28 parts of astragalus, 25-35 parts of floating wheat, 18-28 parts of jujube, 25-35 parts of glutinous rice roots and 50-70 parts of calcined oysters.

[0007] In one embodiment, the Chinese medicine composition includes the following raw materials, measured by mass: 20-25 parts of astragalus, 28-33 parts of floating wheat, 20-25 parts of jujube, 28-33 parts of glutinous rice roots and 55-65 parts of calcined oysters.

[0008] In one embodiment, the Chinese medicine composition includes the following raw materials, measured by mass: 20-22 parts of astragalus, 29-31 parts of floating wheat, 20-22 parts of jujube, 29-31 parts of glutinous rice roots and 58-62 parts of calcined oysters.

[0009] In one embodiment, the Chinese medicine composition is a hypohidrosis-stopping preparation;

[0010] Optionally, the Chinese medicine composition is Xuhanting Granules.

[0011] In one embodiment, the iron deficiency anemia is iron deficiency anemia in children.

[0012] In one embodiment, the adjuvant therapy refers to combined therapy with iron supplements.

[0013] In one embodiment, the iron agent is selected from one or more of iron dextran, compound ferrous sulfate, ferrous fumarate, ferrous gluconate or ferrous succinate.

[0014] In one embodiment, the drug further comprises a pharmaceutically acceptable excipient.

[0015] In one embodiment, the drug is in the form of pills, powders, ointments, tablets, granules, lozenges, capsules, liquids or tinctures.

[0016] Compared with the prior art, this application has the following beneficial effects:

[0017] Through research, the present application has discovered a Chinese medicine composition including astragalus, calcined oyster, floating wheat, glutinous rice root and jujube. After the various components are reasonably matched, the composition has the advantages of obvious effect, low incidence of adverse reactions and good safety when used for auxiliary treatment of iron deficiency anemia, especially iron deficiency anemia in children.

[0018] Furthermore, the efficacy of the Chinese medicine composition of the present application combined with oral iron preparations in the treatment of iron deficiency anemia in children is better than that of iron preparations alone. Specifically, it can effectively improve the children's blood routine indicators and serum iron metabolism indicators, improve the TCM symptom scores and the incidence of adverse reactions, and increase the overall treatment effectiveness, and has good safety. DETAILED DESCRIPTION

[0019] In order to make the above-mentioned purposes, features and advantages of the present application more obvious and easy to understand, the specific implementation methods of the present application are described in detail below. In the following description, many specific details are set forth to facilitate a full understanding of the present application. However, the present application can be implemented in many other ways different from those described herein, and those skilled in the art can make similar improvements without violating the connotation of the present application, so the present application is not limited by the specific embodiments disclosed below.

[0020] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.

[0021] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:

[0022] As used herein, "pharmaceutically acceptable" refers to those ligands, materials, compositions, and / or dosage forms that are suitable for administration to a patient within the scope of sound medical judgment and commensurate with a reasonable benefit / risk ratio.

[0023] As used herein, "pharmaceutically acceptable excipients" refer to pharmaceutically acceptable materials, compositions or vehicles, such as liquid or solid fillers, diluents, excipients, solvents or encapsulating materials. As used herein, the language "pharmaceutically acceptable carriers" includes buffers, sterile water for injection, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are compatible with drug administration. Each carrier must be "pharmaceutically acceptable" in the sense of being compatible with the other ingredients in the formulation and not harmful to the patient. Suitable examples include, but are not limited to: (1) sugars such as lactose, glucose and sucrose; (2) starches such as corn starch, potato starch and substituted or unsubstituted β-cyclodextrins; (3) cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and suppository waxes; (9) oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn starch, etc. Rice oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffered saline; (21) other non-toxic compatible substances used in pharmaceutical preparations.

[0024] As used herein, "drug" includes any agent, compound, composition or mixture that provides physiological and / or pharmacological effects in vivo or in vitro, and often provides beneficial effects. The scope of the physiological and / or pharmacological effects of the "drug" in vivo is not particularly limited, and may be systemic effects or may only produce effects locally. The activity of the "drug" is not particularly limited, and may be an active substance that can interact with other substances, or may be an inert substance that does not interact.

[0025] Herein, a "composition" may be a combination of multiple substances, and further, may be used in combination, or may be a mixture of the combination.

[0026] The percentage content involved in the present invention, unless otherwise specified, refers to mass percentage for solid-liquid mixing and solid-solid mixing, and refers to volume percentage for liquid-liquid mixing.

[0027] As used herein, "one or more" refers to any one, any two, or any two or more of the listed items.

[0028] Herein, "further", "further", "particularly" and the like are used for descriptive purposes to indicate differences in content, but should not be construed as limiting the scope of protection of this application.

[0029] In this application, when it comes to numerical ranges, unless otherwise specified, the above numerical ranges are deemed to be continuous and include the minimum and maximum values ​​of the range, as well as each value between such minimum and maximum values. Further, when a range refers to an integer, each integer between the minimum and maximum values ​​of the range is included. In addition, when multiple ranges are provided to describe features or characteristics, the ranges can be merged. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges included therein.

[0030] The percentage contents involved in this application, unless otherwise specified, refer to mass percentage for solid-liquid mixing and solid-solid mixing, and refer to volume percentage for liquid-liquid mixing.

[0031] The percentage concentrations mentioned in this application, unless otherwise specified, refer to the final concentration, which refers to the percentage of the added component in the system after the addition of the component.

[0032] The invention provides an application of a traditional Chinese medicine composition in preparing a medicine for auxiliary treatment of iron deficiency anemia. The traditional Chinese medicine composition comprises the following raw materials: astragalus, floating wheat, jujube, glutinous rice root and calcined oyster.

[0033] In some of the examples, the Chinese medicine composition includes the following raw materials, measured by mass: 18-28 parts of astragalus, 25-35 parts of floating wheat, 18-28 parts of jujube, 25-35 parts of glutinous rice roots and 50-70 parts of calcined oysters.

[0034] In some of the examples, the Chinese medicine composition includes the following raw materials, measured by mass: 20-25 parts of astragalus, 28-33 parts of floating wheat, 20-25 parts of jujube, 28-33 parts of glutinous rice roots and 55-65 parts of calcined oysters.

[0035] In some of the examples, the Chinese medicine composition includes the following raw materials, measured by mass: 20-22 parts of astragalus, 29-31 parts of floating wheat, 20-22 parts of jujube, 29-31 parts of glutinous rice roots and 58-62 parts of calcined oysters.

[0036] In some of these examples, the Chinese medicine composition is a hypohidrosis-stopping preparation.

[0037] In some of the examples, the Chinese medicine composition is Xuhanting Granules.

[0038] In some of these examples, the adjunctive therapy is combined therapy with iron supplements.

[0039] In some examples, the iron agent is selected from one or more of iron dextran, compound ferrous sulfate, ferrous fumarate, ferrous gluconate or ferrous succinate.

[0040] In some examples, the medicament further includes a pharmaceutically acceptable excipient.

[0041] In some examples, the dosage form of the drug is pills, powders, pastes, tablets, granules, lozenges, capsules, liquids or tinctures. Further, the dosage form of the drug is granules.

[0042] In some of these examples, the drug may be administered by a suitable route of administration according to clinical needs. It is understood that the route of administration of the drug includes, but is not limited to, intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral administration, sublingual administration, nasal administration or transdermal administration. Further, the route of administration of the drug is oral administration.

[0043] In some of the examples, the iron deficiency anemia is iron deficiency anemia in children. Specifically, the Chinese medicine composition of the present application combined with iron preparations for the treatment of iron deficiency anemia in children can effectively improve the blood routine indexes and serum iron metabolism indexes of the children, improve the symptoms of traditional Chinese medicine, and improve the total effective rate of treatment. The efficacy is better than that of dextran iron alone, and the safety is good.

[0044] In some examples, the method for preparing the Chinese medicine composition comprises the following steps:

[0045] Astragalus, floating wheat, jujube and glutinous rice root are decocted and filtered to obtain a first filtrate;

[0046] The calcined oysters are decocted and filtered to obtain a second filtrate;

[0047] The first filtrate was combined with the second filtrate, concentrated, mixed with alcohol, and filtered.

[0048] The following is further described in conjunction with specific embodiments. The raw materials involved in the following specific embodiments, unless otherwise specified, can all be commercially available; the instruments used, unless otherwise specified, can all be commercially available; the processes involved, unless otherwise specified, are all routinely selected by those skilled in the art.

[0049] The following are specific embodiments.

[0050] Example 1

[0051] This embodiment provides an application of a Chinese medicine composition in the preparation of a medicament for the auxiliary treatment of iron deficiency anemia, as follows:

[0052] 1. Objective: To evaluate the efficacy and safety of Xuhanting granules in the adjuvant treatment of iron deficiency anemia in children.

[0053] 2. Materials and methods

[0054] Methods: A total of 72 children with iron deficiency anemia were enrolled and divided into a control group and an observation group according to different treatment plans, with 36 cases in each group. The control group was treated with dextran iron oral liquid alone, and the experimental group was treated with Xuhanting granules on the basis of the control group. Both groups were treated for 4 weeks. The treatment efficacy, blood routine indexes, serum iron metabolism indexes, TCM symptom scores and adverse reactions were compared between the two groups.

[0055] 2.1 General Information

[0056] A total of 72 children with iron deficiency anemia who were treated in the Department of Child Health Care of Guangzhou Women and Children's Medical Center from April 2022 to November 2023 were selected as the research subjects and randomly divided into an observation group and a control group according to the random number table method. There were 36 cases in the observation group, including 23 males and 13 females; the age was (18.28±19.09) months, ranging from 6 to 72 months; the course of disease was (3.14±1.22) months, ranging from 2 to 7 months. There were 36 cases in the control group, including 27 males and 9 females; the age was (17.86±19.18) months, ranging from 6 to 72 months; the course of disease was (3.15±1.49) months, ranging from 2 to 8 months. There was no significant difference in the general data such as gender, age, and course of disease between the two groups (P > 0.05).

[0057] 2.2 Diagnostic criteria

[0058] 2.2.1 Western medicine diagnostic criteria

[0059] Refer to the diagnostic criteria for IDA in children jointly developed by the editorial committee of the Chinese Journal of Pediatrics and other expert groups: (1) Hb (hemoglobin) is reduced, which meets the WHO diagnostic criteria for anemia in children, that is, <110 g / L for children aged 6 months to 6 years and <120 g / L for children aged 6 to 14 years; (2) Peripheral blood red blood cells show microcytic hypochromic changes: mean corpuscular volume (MCV) < 80 fl, mean corpuscular hemoglobin content (MCH) < 27 pg, mean corpuscular hemoglobin concentration (MCHC) < 310 g / L; (3) Iron metabolism test indicators meet the diagnostic criteria for IDA: at least two of the following four items are met: ① serum ferritin (SF) is reduced (< 15 μg / L). It is recommended that serum CRP be tested at the same time to exclude the influence of infection and inflammation on serum ferritin levels as much as possible; ② serum iron (SI) <10.7 μmol / L (60 μg / dl); ③ total iron binding capacity (TIBC) > 62.7 μmol / L (350 μg / dl); ④ Transferrin saturation (TS) < 15%.

[0060] 2.2.2 Standards for TCM Syndrome Differentiation

[0061] Refer to the syndrome differentiation criteria of nutritional anemia spleen and stomach deficiency in the "Standards for Diagnosis and Efficacy of Diseases and Syndromes in Traditional Chinese Medicine for Pediatrics": yellowish or pale face, loss of appetite, fatigue, or diarrhea and loose stools. Pale lips and tongue, thin fur, and weak pulse.

[0062] 2.3 Inclusion criteria

[0063] (1) Those who meet the above-mentioned Western medicine diagnostic criteria and TCM syndrome differentiation criteria; (2) Age 6 months to 6 years old (including the critical value); (3) Disease course ≥ 2 months; (4) Those who actively cooperate with treatment.

[0064] 2.4 Exclusion criteria

[0065] (1) Anemia caused by sideroblastic anemia, thalassemia, persistent bleeding and other factors; (2) Those who have been treated with iron supplements within the past 15 days; (3) Iron absorption and transport disorders caused by gastrointestinal tumors, diarrhea and chronic enteritis; (4) Congenital heart, brain, liver, kidney and lung dysfunction; (5) Those with allergic constitution and clear allergies to the drugs used in this study; (6) Those with clear contraindications to this group of drugs; (7) Those who have participated in other clinical trials in the past two weeks; (8) Those with a history of surgical treatment in the past three months; (9) Other subjects who are considered unsuitable for participation in the trial by the researchers.

[0066] 2.5 Treatment

[0067] The control group was treated with oral dextran iron solution (Kangchen Pharmaceutical (Inner Mongolia) Co., Ltd., specification: 10 mL: 50 mg (Fe), national medicine approval number: H20060084), 4 mL at a time, twice a day, after meals. The treatment lasted for 4 weeks.

[0068] Observation group: On the basis of the control group, Xuhanting granules (Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd., specification: 5g / bag, national medicine approval number: Z44020783) were added for treatment. Children under four years old, 5g once, twice a day; children over four years old, 5g once, 3 times a day. The treatment lasted for 4 weeks.

[0069] 2.6 Observation indicators

[0070] 2.6.1 Main efficacy indicators and their criteria

[0071] Clinical effectiveness: According to the "Guidelines for Clinical Research of New Chinese Medicines (Trial)" [9] The efficacy of the two groups of children was evaluated according to the following criteria: clinical symptoms basically disappeared, hemoglobin reached above normal values ​​or increased by 10-20 g / L for marked efficacy; clinical symptoms significantly improved, and hemoglobin level increased by 5-10 g / L for effective; clinical symptoms did not improve, and hemoglobin level did not change for ineffective. The total clinical effective rate = (number of markedly effective cases + number of effective cases) / total number of cases × 100%.

[0072] 2.6.2 Secondary efficacy indicators

[0073] (1) Routine blood test indicators: red blood cell count (RBC), hemoglobin (HGB), mean corpuscular hemoglobin (MCH), and red blood cell volume (MCV) were measured in the two groups before and after treatment; (2) Serum iron metabolism indicators: serum iron (SI), ferritin (SF), and serum total iron binding capacity (TIBC) were measured in the two groups before and after treatment; (3) TCM symptom score: poor appetite, yellow face, abdominal distension, sweating, mental fatigue, and irritability were divided into asymptomatic (0 points), mild (2 points), moderate (4 points), and severe (6 points) according to the severity of the symptoms.

[0074] 2.6.3 Safety indicators

[0075] Observe possible complications and adverse reactions, including symptoms, signs, laboratory tests, etc. Analyze the causes of adverse reactions and calculate the incidence of adverse reactions.

[0076] 2.7 Statistical analysis

[0077] SPSS software was used to analyze the original data. The measurement data were expressed as mean ± SD and the t test was used. The count data were expressed as percentage (%) and the chi-square test was used. 2P < 0.05 indicated statistically significant differences.

[0078] 3. Results

[0079] 3.1 Comparison of clinical efficacy

[0080] After 4 weeks of treatment, the total clinical effective rate of the observation group was 94.4%, which was significantly higher than 72.2% of the control group (P < 0.05), see Table 1.

[0081] Table 1 Clinical effective rate of the two groups of children [cases (%)]

[0082]

[0083] Note: Compared with the control group △ P < 0.05.

[0084] 3.2 Comparison of blood routine indicators

[0085] Before treatment, there was no significant difference in the blood routine indicators (RBC, HGB, MCH, MCV) between the two groups. After 4 weeks of treatment, the blood routine indicators of the two groups were significantly higher than before treatment. The levels of RBC, HGB and MCH in the observation group were significantly higher than those in the control group, as shown in Table 2.

[0086] Table 2 Comparison of blood routine indicators between the two groups of children before and after treatment (x±s)

[0087]

[0088] Note: Compared with the same group before treatment * P < 0.05, compared with the control group after treatment △ P < 0.05.

[0089] 3.3 Comparison of serum iron metabolism indicators

[0090] Before treatment, there were no significant differences in serum iron metabolism indices (SI, SF, TIBC) between the two groups. After 4 weeks of treatment, the SI and SF levels of the two groups were significantly higher than those before treatment, and the TIBC level was significantly lower than that before treatment. The SI and SF levels of the observation group were significantly higher than those of the control group, and the TIBC level was significantly lower than that of the control group, as shown in Table 3.

[0091] Table 3 Comparison of serum iron metabolism indexes between the two groups of children before and after treatment (x±s)

[0092]

[0093] Note: Compared with the same group before treatment * P < 0.05, compared with the control group after treatment △ P < 0.05.

[0094] 3.4 Comparison of TCM symptom scores

[0095] Before treatment, there was no significant difference in the TCM symptom scores between the two groups; after 4 weeks of treatment, the TCM symptom scores of the two groups were significantly lower than before treatment, and the symptom scores of poor appetite, sweating, and mental fatigue in the observation group were significantly lower than those in the control group, see Table 4.

[0096] Table 4 TCM symptom scores of the two groups of children before and after treatment (x±s)

[0097]

[0098] Note: Compared with the same group before treatment * P < 0.05, compared with the control group after treatment △ P < 0.05.

[0099] 3.5 Comparison of adverse reaction rates

[0100] During the treatment, the incidence of adverse reactions in the observation group was 11.1%, and the incidence of adverse reactions in the control group was 22.2%. There was no significant difference in the incidence of adverse reactions between the two groups, as shown in Table 5.

[0101] Table 5 Incidence of adverse reactions in the two groups of children after treatment [cases (%)]

[0102]

[0103] In summary, after 4 weeks of treatment, the total clinical effective rate of the observation group was 94.4%, which was significantly higher than 72.2% of the control group. The blood routine indicators of the observation group, including red blood cell count (RBC), hemoglobin (HGB), and mean hemoglobin content (MCH), were significantly higher than those of the control group; serum iron (SI) and ferritin (SF) levels were significantly higher than those of the control group, and serum total iron binding capacity (TIBC) level was significantly lower than that of the control group; the score of TCM symptoms (poor appetite, hyperhidrosis, and mental fatigue) was significantly lower than that of the control group. There was no significant difference in the incidence of adverse reactions between the two groups. Xuhanting granules combined with iron dextran can effectively improve the blood routine indicators and serum iron metabolism indicators of children with iron deficiency anemia, improve TCM symptoms, and improve the total effective rate of treatment. The efficacy is better than that of iron dextran alone, and the safety is good.

[0104] 4. Discussion

[0105] Children grow and develop rapidly, and their bodies have a great demand for iron. Insufficient iron reserves will lead to abnormal synthesis of hemoglobin, inability of red blood cells in the blood to carry oxygen normally, and the human body cannot obtain enough oxygen, resulting in symptoms of anemia such as fatigue and shortness of breath. The Chinese medicine syndrome differentiation of iron deficiency anemia is mainly spleen and stomach weakness, spleen and kidney deficiency, deficiency of both heart and spleen qi and blood, liver and kidney yin deficiency, etc., among which spleen and stomach qi deficiency syndrome is the most common. Xuhanting Granules are composed of Astragalus, calcined oyster, floating wheat, glutinous rice root and jujube. The functions and indications are to nourish qi and yin, consolidate the surface and restrain sweat. It is used for spontaneous sweating, night sweats and night sweats in children due to insufficient qi and yin. All the medicinal flavors in the formula are Chinese medicines that are both medicinal and edible, so they are highly safe for the treatment of iron deficiency anemia in children. Among them, Astragalus strengthens the spleen and replenishes qi, jujube strengthens the spleen and replenishes qi, helps to produce blood, nourishes blood and replenishes blood, and calcined oyster astringes and stops sweating.

[11] , glutinous rice roots and floating wheat nourish qi, nourish yin and stop sweating.

[0106] From the analysis of modern pharmacological components, the main chemical components contained in Astragalus include Astragalus polysaccharides, saponin compounds, flavonoids, amino acids and trace elements. Studies have found that Astragalus polysaccharide iron can significantly increase the red blood cell count, hemoglobin, serum iron and serum ferritin content of anemic mice, and its therapeutic effect is better than ferrous sulfate and dextran iron. Jujube mainly contains chemical components such as glycosides, polyphenols, flavonoids, triterpene acids, alkaloids, amino acids, vitamins and inorganic elements. The main active ingredient of jujube in replenishing qi and generating blood is polysaccharide, which effectively improves qi and blood deficiency syndrome by regulating whole blood cells and energy metabolism, promoting bone marrow hematopoiesis, and stimulating immunity. Pharmacological studies have found that jujube extract has a significant improvement effect on hematological indicators such as HGB, HCT, RBC and PLT in rats with iron deficiency anemia, and can significantly increase the serum iron content, iron saturation and iron content in the liver of rats with iron deficiency anemia, and significantly reduce the serum unsaturated iron binding capacity. Glutinous rice root contains a variety of amino acids, sugars and flavonoids, which can be used to treat childhood sweating

[17] The main components of floating wheat are protein, sugar, etc., which have significant therapeutic effects on improving hyperhidrosis and depression.

[0107] At present, exogenous iron supplementation is a direct and effective way to treat iron deficiency anemia. However, some children with iron deficiency anemia have low iron absorption rate due to incomplete development of the digestive system, so the clinical effect is not good; in addition, iron preparations have certain irritation to the digestive tract and have a high incidence of adverse reactions. This study used a combination of Chinese and Western medicine to treat children with iron deficiency anemia. On the one hand, oral iron preparations were used to directly increase the blood iron level of the children. On the other hand, Xuhanting granules were used to strengthen the spleen and replenish qi, improve the symptoms of yellow face, poor appetite, sweating, mental fatigue caused by weak spleen and stomach in children, and may increase the absorption rate of iron in children. The clinical effect is better, and there is no increased risk of adverse reactions. It is a reliable method for treating iron deficiency anemia in children.

[0108] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0109] The above-described embodiments only express several implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be construed as limiting the scope of the patent application. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present application, and these all belong to the protection scope of the present application. Therefore, the protection scope of the patent application shall be subject to the attached claims, and the description may be used to interpret the content of the claims.

Claims

1. Use of a Chinese medicine composition in preparing a medicine for auxiliary treatment of iron deficiency anemia, the Chinese medicine composition comprising the following raw materials: astragalus, floating wheat, jujube, glutinous rice root and calcined oyster.

2. The use according to claim 1, characterized in that: The Chinese medicine composition comprises the following raw materials in parts by mass: 18 to 28 parts of astragalus, 25 to 35 parts of floating wheat, 18 to 28 parts of jujube, 25 to 35 parts of glutinous rice roots and 50 to 70 parts of calcined oysters.

3. The use according to claim 1, characterized in that: The Chinese medicine composition comprises the following raw materials in parts by mass: 20-25 parts of astragalus, 28-33 parts of floating wheat, 20-25 parts of jujube, 28-33 parts of glutinous rice roots and 55-65 parts of calcined oysters.

4. The use according to claim 1, characterized in that: The Chinese medicine composition comprises the following raw materials in parts by mass: 20-22 parts of astragalus, 29-31 parts of floating wheat, 20-22 parts of jujube, 29-31 parts of glutinous rice roots and 58-62 parts of calcined oysters.

5. The use according to claim 1, characterized in that: The Chinese medicine composition is a hypohidrosis-stopping preparation; Optionally, the Chinese medicine composition is Xuhanting Granules.

6. The use according to claim 1, characterized in that: The iron deficiency anemia is iron deficiency anemia in children.

7. The use according to claim 1, characterized in that: The adjuvant therapy refers to combined therapy with iron preparations.

8. The use according to claim 7, characterized in that: The iron agent is selected from one or more of iron dextran, compound ferrous sulfate, ferrous fumarate, ferrous gluconate or ferrous succinate.

9. The use according to any one of claims 1 to 8, characterized in that: The drug also includes pharmaceutically acceptable excipients.

10. The use according to any one of claims 1 to 8, characterized in that: The dosage form of the medicine is pill, powder, paste, tablet, granule, lozenge, capsule, liquid or tincture.